Premium
Reverse and Forward Translational Neuropharmacology in Psychiatric Drug Discovery
Author(s) -
Shaffer Christopher L.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.901
Subject(s) - neuropharmacology , clinical trial , medicine , parallels , drug , clinical pharmacology , drug development , psychiatry , disease , population , psychology , neuroscience , intensive care medicine , pharmacology , environmental health , mechanical engineering , engineering
The probability of achieving marketing approval of a novel therapeutic for psychiatric indications is extremely low due largely to the inability to demonstrate durable and reproducible efficacy in phase II trials and beyond. These failures are often attributed to the lack of translation of the underlying neuropharmacology from animal model(s) to the disease population. However, how assured is such a conclusion considering the clinical efficacy path rarely meticulously parallels the preclinical experiment(s) that underwrote it?